Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The effects of different i.v. doses of glucagon-like peptide 1 (GLP-1) on glucose homeostasis and gastric emptying were compared in patients with type 2 diabetes. Twelve patients with type 2 diabetes received three different infusion rates of GLP-1 (0.4, 0.8, and 1.2 pmol/kg x min) or placebo in the fasting state and after a solid test meal (containing [(13)C]octanoic acid). Blood was drawn for glucose, insulin, C-peptide, glucagon, and GLP-1 determinations. The gastric emptying rate was calculated from the (13)CO(2) excretion rates in breath samples. Statistics were determined using repeated measures ANOVA and Duncan's post hoc test. Plasma glucose concentrations were equally normalized with all GLP-1 doses (P < 0.001). Insulin and C-peptide concentrations dose-dependently rose during GLP-1 infusion in the fasting state (P < 0.05), but were dose-dependently reduced by GLP-1 after meal ingestion (P = 0.0031 and 0.0074, respectively). Glucagon secretion was suppressed with GLP-1. Gastric emptying was decelerated by GLP-1 in a dose-dependent fashion (P < 0.001). Despite a dose-dependent stimulation of insulin secretion, glucose normalization can be achieved even with 0.4 pmol GLP-1/kg x min. Due to the dose-dependent inhibition of gastric emptying, lower GLP-1 doses than previously used may be as suitable for glucose control in patients with type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This dosing regimen produced supraphysiological plasma levels and normalized blood glucose concentrations in type II DM (23).”
From Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans (2008) · cites this paper as [23]
In the citing paper
“The inhibitory effect of GLP-1 on gastric emptying is dose-dependent, and the use of lower doses of GLP-1 in patients with T2DM may also be suitable for blood glucose control (141).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [141]
In the citing paper
“The inhibitory effect of GLP-1 on gastric emptying is dose-dependent, and the use of lower doses of GLP-1 in patients with T2DM may also be suitable for blood glucose control (141).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [141]
In the citing paper
“Furthermore, the action of GLP-1 and GLP-1 RAs (especially short acting) on gastric and intestinal cells causes, respectively, the deceleration of gastric emptying [31] and the reduction in intestine motility [32], which both impact the absorption of nutrients.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [31]
Citations
Cites
Intensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Self-citationZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“Nausea and vomiting have previously been reported after the administration of high GLP-1 doses in some (15, 18), but not all, studies (8, 21, 22).”
ResultSelf-citationMalmberg, K. (1997) · BMJ · doi:10.1136/bmj.314.7093.1512 · Cited by 1,286
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 3×
“However, in most previous studies comparably high doses of GLP-1 have been chosen for infusion (1, 9, 14).”
BackgroundResultSelf-citationGhoos, Y. F., Maes, B. D., Geypens, B. J., Mys, G., Hiele, M. I., Rutgeerts, P. J., & Vantrappen, G. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90640-x · Cited by 946
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Self-citationStudies of pancreatic alpha cell function in normal and diabetic subjects
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106297 · Cited by 837
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationNauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
Self-citationMitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260104 · Cited by 595 · cited 1×
“Delayed insulin secretion after meal ingestion causes reduced suppression of hepatic glucose output as well as glucagon secretion, leading to postprandial hyperglycemia (31).”
BackgroundGlucagon-like peptide-1: a potent regulator of food intake in humans
Gutzwiller, J.-P., Göke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., Winterhalder, R., Conen, D., & Beglinger, C. (1999) · Gut · doi:10.1136/gut.44.1.81 · Cited by 576
Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.
Polonsky, K. S., Given, B. D., Hirsch, L. J., Tillil, H., Shapiro, E. T., Beebe, C., Frank, B. H., Galloway, J. A., & Van Cauter, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181903 · Cited by 567 · cited 1×
“Type 2 diabetes is characterized by a progressive loss of first phase insulin secretion and a compensatory increased second phase secretion (29, 30).”
BackgroundAdmission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial
Bruno, A., Levine, S. R., Frankel, M. R., Brott, T. G., Lin, Y., Tilley, B. C., Lyden, P. D., Broderick, J. P., Kwiatkowski, T. G., Fineberg, S. E., et al. (2002) · Neurology · doi:10.1212/wnl.59.5.669 · Cited by 516
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · cited 1×
“However, in most previous studies comparably high doses of GLP-1 have been chosen for infusion (1, 9, 14).”
ResultSelf-citationBiological actions and therapeutic potential of the glucagon-like peptides
Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 500
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Self-citationExendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Edwards, C. M. B., Stanley, S. A., Davis, R., Brynes, A. E., Frost, G. S., Seal, L. J., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421 · cited 6×
“• Dose-Response Relationship for GLP J Clin Endocrinol Metab, June 2003, 88(6):2719–2725 2723”
BackgroundInfluentialThe role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus
Pratley, R. E., & Weyer, C. (2001) · Diabetologia · doi:10.1007/s001250100580 · Cited by 419
Carson, J. L., Scholz, P. M., Chen, A. Y., Peterson, E. D., Gold, J., & Schneider, S. H. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01969-1 · Cited by 410
Gastric and oesophageal emptying in patients with Type 2 (non-insulin-dependent) diabetes mellitus
Horowitz, M., Harding, P. E., Maddox, A. F., Wishart, J. M., Akkermans, L. M. A., Chatterton, B. E., & Shearman, D. J. C. (1989) · Diabetologia · doi:10.1007/bf00265086 · Cited by 392
Gastric emptying in diabetes: clinical significance and treatment
Horowitz, M., O’Donovan, D., Jones, K. L., Feinle, C., Rayner, C. K., & Samsom, M. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00658.x · Cited by 308 · cited 3×
“This is in line with the absence of gastrointestinal symptoms in patients with diabetes who have a proven deceleration of gastric emptying (gastroparesis) (19, 33, 34).”
BackgroundBraden, B., Adams, S., Duan, L.-P., Orth, K.-H., Maul, F.-D., Lembcke, B., Hör, G., & Caspary, W. F. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90202-3 · Cited by 294
Juhl, C. B., Hollingdal, M., Sturis, J., Jakobsen, G., Agersø, H., Veldhuis, J., Pørksen, N., & Schmitz, O. (2002) · Diabetes · doi:10.2337/diabetes.51.2.424 · Cited by 264
Meier, J. J., Hücking, K., Holst, J. J., Deacon, C. F., Schmiegel, W. H., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2497 · Cited by 230
Self-citationRitzel, R., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 210
Self-citationHolst, J. J. (1982) · Biochemical Journal · doi:10.1042/bj2070381 · Cited by 176
Self-citationLarsen, J., Hylleberg, B., Ng, K., & Damsbo, P. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1416 · Cited by 171
Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives
Meier, J. J., Gallwitz, B., Schmidt, W. E., & Nauck, M. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01434-6 · Cited by 146
Self-citationGlucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes
Nauck, M. A., Holst, J. J., Willms, B., & Schmiegel, W. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211750 · Cited by 145
Self-citationGastric emptying in diabetic autonomic neuropathy.
Campbell, I. W., Heading, R. C., Tothill, P., Buist, T. A., Ewing, D. J., & Clarke, B. F. (1977) · Gut · doi:10.1136/gut.18.6.462 · Cited by 136
Rachman, J., Gribble, F. M., Barrow, B. A., Levy, J. C., Buchanan, K. D., & Turner, R. C. (1996) · Diabetes · doi:10.2337/diab.45.11.1524 · Cited by 119
Schirra, J. R. J., Kuwert, P., Wank, U., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1997) · PubMed · Cited by 100
Upper gastrointestinal symptoms in a U.S. national sample of adults with diabetes
J. A. Ricci, R. S. (2000) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655200750024317 · Cited by 99
Meneilly, G. S., McIntosh, C. H. S., Pederson, R. A., Habener, J. F., Gingerich, R., Egan, J. M., Finegood, D. T., & Elahi, D. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1951 · Cited by 63
Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes
Zander, M., Taskiran, M., Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.720 · Cited by 61
Self-citation
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Self-citationThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“…cirrhosis and basal hyperglucagonemia (Dupre et al., 1991) and in human and animal models during euglycemic conditions (Pederson and Brown, 1978; Meier et al., 2003b), but in healthy persons under hyperglycemic conditions or in T2DM, no GIP effects on glucagon secretion were reported (Nauck et…”
BackgroundLong-term Results of Laparoscopic Sleeve Gastrectomy for Obesity
Himpens, J., Dobbeleir, J., & Peeters, G. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181e90b31 · Cited by 807
Metadata
- Authors
- Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A.
- Affiliations
- St. Josef-Hospital (DE)
- University of Copenhagen (DK)
- Diabeteszentrum Bad Lauterberg (DE)
- Corresponding author
- Meier, Juris J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-06
- Volume
- 88
- Issue
- 6
- Pages
- 2719-2725
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1987182389
- Cited by
- 369
- References
- 39
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 7 · 2021: 10 · 2020: 11 · 2019: 13 · 2018: 16 · 2017: 14 · 2016: 12 · 2015: 20 · 2014: 31 · 2013: 18 · 2012: 18
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, type 2 diabetes, glucose homeostasis, gastric emptying, insulin secretion, C-peptide, glucagon secretion, dose-response relationship, solid meal, breath test, intravenous infusion
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Fasting, Female, Gastric Emptying, Glucagon, Humans, Injections, Intravenous, Male, Middle Aged, Osmolar Concentration, Peptide Fragments, Protein Precursors, Time Factors, Postprandial Period, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.